[{"orgOrder":0,"company":"Neuron23","sponsor":"Westlake Village BioPartners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"LRRK2","graph1":"Neurology","graph2":"Preclinical","graph3":"Neuron23","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Neuron23 \/ Westlake Village BioPartners","highestDevelopmentStatusID":"4","companyTruncated":"Neuron23 \/ Westlake Village BioPartners"},{"orgOrder":0,"company":"Neuron23","sponsor":"Redmile Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Series B Financing","leadProduct":"Undisclosed","moa":"LRRK2","graph1":"Neurology","graph2":"Preclinical","graph3":"Neuron23","amount2":0.080000000000000002,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Neuron23 \/ Redmile Group","highestDevelopmentStatusID":"4","companyTruncated":"Neuron23 \/ Redmile Group"},{"orgOrder":0,"company":"Neuron23","sponsor":"Qiagen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"LRRK2","graph1":"Neurology","graph2":"Preclinical","graph3":"Neuron23","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Neuron23 \/ Qiagen","highestDevelopmentStatusID":"4","companyTruncated":"Neuron23 \/ Qiagen"},{"orgOrder":0,"company":"Neuron23","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"NEU-411","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Neuron23","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Neuron23 \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Neuron23 \/ Not Applicable"},{"orgOrder":0,"company":"Neuron23","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"NEU-411","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Neuron23","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Neuron23 \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Neuron23 \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Neuron23","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"NEU-111","moa":"","graph1":"Immunology","graph2":"Phase I","graph3":"Neuron23","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Neuron23 \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Neuron23 \/ Not Applicable"}]